antibodies - online.com







anti-C3a antibody (Biotin)



Publications



()	11/	IN	/ie	A .
	/ // 	۱ ات	/ (−	' \/\/

Quantity:	50 µg
Target:	C3a
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This C3a antibody is conjugated to Biotin
Application:	Western Blotting (WB)
Product Details	
Clone:	474
Sterility:	0.2 μm filtered
Target Details	
Target:	C3a
Alternative Name:	c3/c3a (C3a Products)
Background:	Monoclonal antibody 474 reacts with an epitope on C3a. The antibody reacts both with intact C3 as with C3a. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. During complement activation, C3 is proteolytically cleaved resulting in release of the anaphylatoxic peptide C3a. C3a is a small polypeptide consisting of

74 amino acids (ca.10 kDa). C3a itself is very short-lived and in serum cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP). C3a exerts its function through a specific receptor (C3aR), which belongs to the G-protein coupled receptor family. Expression of C3aR has been reported in many cell types including myeloid and non-myeloid cells. Expression of C3aR on haematopoietic stem/progenitor cells has been shown to promote the trafficking/homing of these cells to the BM. Engagement of C3aR on DCs and T cells has been shown to up-regulate these cell functions. C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Aliases Complement component 3 Immunogen C3a

Pathways:

Complement System

Application Details

Λnn	lication	Motae.
-	IICALIOLL	TACHES.

For Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting. Positive Human serum control Negative Serum of C3 deficient patients control 1

Restrictions:

For Research Use only

Handling

Buffer:	PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.	
Preservative:	Sodium azide	
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.	
Storage:	4 °C	
Storage Comment:	Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.	

Publications

Product cited in:

Bax, Siersema, Haringsma, Kuipers, Vos, Van Dekken, Van Vliet, Kusters: "High-grade dysplasia in Barrett's esophagus is associated with increased expression of calgranulin A and B." in:

Scandinavian journal of gastroenterology, Vol. 42, Issue 8, pp. 902-10, (2007) (PubMed).